ReNetX adds Dr. Kevin Malobisky to SAB

ReNetX Bio has added Dr. Kevin Malobisky to its Scientific Advisory Board. Dr. Malobisky, currently the Chief Regulatory and Strategic Operations Officer at Tavanta Therapeutics, brings over 30 years of executive leadership and global drug development experience to the advisory role.

“Dr. Malobisky brings extensive experience and success in achieving significant
regulatory milestones such as Breakthrough Therapy and Fast Track Designation for novel therapies,” said ReNetX CEO Erika R. Smith.